

Epioxa® HD and Epioxa®

EPIOXA HD (riboflavin 5'-phosphate ophthalmic solution) 0.239%, for topical ophthalmic use
EPIOXA (riboflavin 5'-phosphate ophthalmic solution) 0.177%, for topical ophthalmic use

A guide to help your office navigate the acquisition of Epioxa

Please see Important Safety Information on last page.
For full Prescribing Information, please visit www.epioxa.com.

Specialty Pharmacy (SP)



Ordering Epioxa® though Specialty Pharmacy

Epioxa can be procured through the Orsini Specialty Pharmacy. Submit the patient enrollment form (PEF) to EpioxaCareConnect™ (ECC) and select the SP box on the PEF:

Fax 1-877-860-2146 | Email: Epioxaliation@orsinihc.com



For more information on patient financial assistance programs, contact your Reimbursement Liaison.


Buy and Bill



Purchase Epioxa® from Glaukos

Epioxa can be purchased directly from Glaukos. To place an order, contact Glaukos Customer Service:

Fax 1-781-768-3401 | Email USAOrders@glaukos.com



For more information on patient financial assistance programs, contact your Reimbursement Liaison.

Epioxa® Coding

10-digit NDC	25357-024-01
11-digit NDC	25357-0024-01
NDC Description	One single-dose glass syringe containing 2 mL of EPIOXA HD 0.239% packaged in a foil pouch One single-dose glass syringe containing 2 mL of EPIOXA 0.177% packaged in a foil pouch
HCPCS Code	J2789
HCPCS Descriptor	Riboflavin 5'-phosphate, ophthalmic solution (Epioxa HD/Epioxa), up to 2 mL

Effective July 1, 2026, Epioxa should be reported using its permanent HCPCS code, J2789. Each epithelium-on corneal cross-linking kit contains one 2 mL syringe of Epioxa HD 0.239% and one 2 mL syringe of Epioxa 0.177%. One billing unit of J2789 represents up to 2 mL. Therefore, one complete Epioxa treatment kit is reported as 2 billing units of J2789. Confirm any plan-specific requirements prior to billing.

Epithelium-on Corneal Cross-Linking Kit

Each kit includes:



One single-dose glass syringe containing 2 mL of **EPIOXA HD 0.239%** packaged in a foil pouch.
One single-dose glass syringe containing 2 mL of **EPIOXA 0.177%** packaged in a foil pouch.



Boost Goggles® Kit

- Boost Goggles®
- Tube Set
- Head Strap



Treatment Activation Card

Other Supplies Needed

Each provider office will need to obtain an O₂n™ System prior to an Epioxa® corneal cross-linking procedure.

Before treatment, have the following items available:

- Medical grade oxygen source with pressure regulator and flow meter (recommend an aluminum size D or E with integrated valve and regulator and metered flow rate of 1 liter per minute (LPM))
- Humidifier with pressure relief valve and tapered barb fitting
- Humidifier connector tube, 15”
- Humidifier bottle bracket
- Lid speculum
- Oxygen sensing meter, such as Quantek Model 901 or equivalent

The following supplies are also recommended:

- Betadine®
- Balanced Salt Solution (BSS®)
- Weck-cel® spear sponge
- 4x4 gauze
- Speculum (45° recommended; no greater than 70 mm)
- Tegaderm™
- Anesthetic drops
- Pachymeter
- Bandage contact lens
- Postoperative medication


Dosing and Administration

Dosage: EPIOXA HD ophthalmic solution 0.239% (2.39 mg/mL) riboflavin 5'-phosphate (single-dose glass syringe). EPIOXA ophthalmic solution 0.177% (1.77 mg/mL) riboflavin 5'-phosphate (single-dose glass syringe).¹

Administration: For topical ophthalmic use only. NOT for injection or intraocular use. Supplied in single-dose syringes; discard opened syringes after use. For use with the O₂n System and Boost Goggles only (refer to device manuals/user guide for device instructions).¹⁻⁴

Storage: Co-packaged Epithelium-on Cross-linking Kit (NDC 25357-024-01) containing one 2 mL single-dose syringe of EPIOXA HD 0.239% and one 2 mL single-dose syringe of EPIOXA 0.177% (foil pouches). Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Minimize exposure of syringes to light once removed from protective packaging.¹


Support and Resources




EpioxaCareConnect™ simplifies the process with a dedicated team that partners with your office to streamline access and logistics.

[Link to EpioxaCareConnect](#) ➔

Practice Resources




Billing and Coding Guide



Billing and Coding Quick Guide



EpioxaCareConnect HCP Brochure




EpioxaCareConnect PAL Patient Brochure

EpioxaCareConnect™

Eligible commercially insured **patients** may pay as little as **\$0***



Out-of-pocket
For the cost of Epioxa®*



Out-of-pocket
For the cost of the cross-linking procedure*



To get started, scan the QR code or call
1-855-5-EPIOXA
1-855-537-4692

*Financial support is available for commercially insured eligible patients only. Additional restrictions may apply. Subject to change.

For full terms and conditions, visit [Epioxa.com](https://www.epioxa.com)
See Program Terms, Conditions, and Eligibility

Indication and Important Safety Information

INDICATIONS AND USAGE

EPIOXA® HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA® (riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients ages 13 years and older, in conjunction with the O₂n™ system and the Boost Goggles®.

IMPORTANT SAFETY INFORMATION

Contraindications

EPIOXA® HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride (BAC) or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

Warnings and Precautions

Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

Adverse Reactions

The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

Dosage and Administration

EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use.

EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use.

EPIOXA HD and EPIOXA are for use with the O₂n System and Boost Goggles only.

Refer to the [O₂n System Operator's Manual and Boost Goggles User Guide](#) for device instructions.

Please see full Prescribing Information for EPIOXA HD and EPIOXA at www.Epioxa.com.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

Disclaimer: Glaukos provides this Acquisition Guide for informational purposes only, and it is subject to change without notice. This guide is intended to provide general information regarding the acquisition and procurement considerations for Glaukos products. It is not intended to provide instruction on billing, coding, coverage, or payment, nor should it be interpreted as a guarantee of reimbursement or payer coverage. It is the responsibility of providers, physicians, facilities, and suppliers to determine appropriate processes for purchasing, inventory management, and product use in accordance with their institutional policies and applicable payer requirements. Providers and facilities should contact their distributors, specialty pharmacies, or third-party payers, as applicable, for current information regarding ordering processes, product availability, and coverage policies. For further detailed product information, including indications for use, contraindications, effects, precautions, and warnings, please consult the product's Instructions for Use (IFU) or prescribing information (PI) prior to use. The information provided herein is without any other warranty or guarantee of any kind, expressed or implied, as to completeness, accuracy, or otherwise.

References: **1.** Glaukos Corporation. (2025). EPIOXA® HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA® (riboflavin 5'-phosphate ophthalmic solution) 0.177% [Prescribing Information](#). **2.** Glaukos Corporation. (2024). EPIOXA® epithelium-on corneal cross-linking system: Instructions for use. <https://www.epioxa.com> **3.** Glaukos Corporation. (2024). [O₂n™ corneal cross-linking system operator's manual](#). **4.** Glaukos Corporation. (2024). [Boost Goggles® user guide](#).